Category - Developments

Developments

Merus treats first patient with MCLA-145 in Phase 1 trial for solid tumors

Merus (NASDAQ:MRUS) treated the first patient with MCLA-145, a bispecific antibody therapeutic candidate, in its Phase 1 trial for the treatment of solid tumors. MCLA-145 is an immunostimulatory molecule that binds to...

May 10, 2019

Developments

Genetic Technologies validates two cancer risk assessment tests

Genetic Technologies (ASX:GTC; NASDAQ:GENE) has validated risk assessment tests for colorectal cancer in individuals with no known pathogenic gene variant, and for breast cancer in individuals who do not have a family...

May 10, 2019

Developments

uniQure reports new Phase 2b data for hemophilia B gene therapy candidate

uniQure (NASDAQ:QURE) reported new data from its Phase 2b trial of hemophilia B candidate, AMT-061, which demonstrated sustained activity six months after administration in three patients. AMT-061 is a therapy that...

May 10, 2019

Developments

FDA accepts Esperion NDAs for LDL cholesterol-lowering candidates

The FDA has accepted Esperion’s (NASDAQ:ESPR) NDAs for its bempedoic acid and bempedoic acid-ezetimibe combination tablets for the treatment of elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid and...

May 9, 2019

Developments

Zenabis Global and Heritage Cannabis to enter mutual supply and services agreements

Zenabis Global (TSXV:ZENA) and Heritage Cannabis (CSE:CANN; OTC:HERTF) signed a supply and services agreement for Zenabis to supply dried cannabis flower to Heritage for the extraction of CBD and THC. The term sheet...

May 9, 2019

Developments

Biohaven Pharma reports new Phase 2/3 data for rimegepant for migraines

Biohaven Pharmaceutical Holding (NYSE:BHVN) reported new data from its Phase 2/3 trial of rimegepant, and orally-dosed calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraines. During the third...

May 9, 2019

Developments

Alder BioPharma reports new Phase 3 data for eptinezumab for migraines

Alder BioPharma (NASDAQ:ALDR) reported new data from its Phase 3 trial of eptinezumab, a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP), for the prevention of migraines. Nearly 60% of patients...

May 9, 2019

Developments

Tilray to boost Canadian cannabis production and manufacturing

Tilray (NASDAQ:TLRY) plans to spend $32.6-million to increase its Canadian cannabis production and manufacturing capacity by 203,000 square feet at three plants. The three Canadian sites are at Leamington and London...

May 8, 2019

Developments

IntelGenx and Aquestive Therapeutics in global collaboration for Tadalafil

IntelGenx (TSXV:IGX; OTCQX:IGXT) entered into a definitive worldwide agreement with Aquestive Therapeutics (NASDAQ:AQST), a specialty pharmaceutical company, for the co-development and commercialization of Tadalafil...

May 8, 2019

Developments

Theralase receives notice of acceptance from Chinese Patent Office

The Chinese Patent Office issued a notice of acceptance to Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) for a patent application about its multi-wavelength photodynamic therapy (PDT). The patent validates the...

May 7, 2019

Category - Developments

Merus treats first patient with MCLA-145 in Phase 1 trial for solid tumors

Genetic Technologies validates two cancer risk assessment tests

uniQure reports new Phase 2b data for hemophilia B gene therapy candidate

FDA accepts Esperion NDAs for LDL cholesterol-lowering candidates

Zenabis Global and Heritage Cannabis to enter mutual supply and services agreements

Biohaven Pharma reports new Phase 2/3 data for rimegepant for migraines

Alder BioPharma reports new Phase 3 data for eptinezumab for migraines

Tilray to boost Canadian cannabis production and manufacturing

IntelGenx and Aquestive Therapeutics in global collaboration for Tadalafil

Theralase receives notice of acceptance from Chinese Patent Office

General

More